University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Select or Award-Winning Individual Scholarship

Supervised Undergraduate Student Research
and Creative Work

Spring 5-2022

Unraveling the Molecular Foundations Behind the Diverged
Behaviors of Mouse Insulin 1 and Insulin 2, Connecting Diabetes
Risk with Glucocorticoid Treatment and Chronic Migraine through
the Analysis of Islet Chemistry, and Capturing Key
Posttranslational Modifications All Through the Application of a
Novel LC-IMS-MS Workflow
Connor Christopher Long
University of Tennessee, Knoxville, clong54@vols.utk.edu

Follow this and additional works at: https://trace.tennessee.edu/utk_selectug
Part of the Analytical Chemistry Commons, Endocrine System Diseases Commons, MedicinalPharmaceutical Chemistry Commons, and the Molecular Biology Commons

Recommended Citation
Long, Connor Christopher, "Unraveling the Molecular Foundations Behind the Diverged Behaviors of
Mouse Insulin 1 and Insulin 2, Connecting Diabetes Risk with Glucocorticoid Treatment and Chronic
Migraine through the Analysis of Islet Chemistry, and Capturing Key Posttranslational Modifications All
Through the Application of a Novel LC-IMS-MS Workflow" (2022). Select or Award-Winning Individual
Scholarship.
https://trace.tennessee.edu/utk_selectug/18

This Article is brought to you for free and open access by the Supervised Undergraduate Student Research and
Creative Work at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Select
or Award-Winning Individual Scholarship by an authorized administrator of TRACE: Tennessee Research and
Creative Exchange. For more information, please contact trace@utk.edu.

Unraveling the Molecular Foundations Behind the Diverged Behaviors
of Mouse Insulin 1 and Insulin 2, Connecting Diabetes Risk with
Glucocorticoid Treatment and Chronic Migraine through the Analysis
of Islet Chemistry, and Capturing Key Posttranslational Modifications
All Through the Application of a Novel LC-IMS-MS Workflow

An Honors Thesis Presented for the
Bachelor of Science
Degree
The University of Tennessee, Knoxville

Connor C. Long
May 2022
Copyright © 2022 by Connor C. Long
All rights reserved.

ii

ACKNOWLEDGEMENTS
I would like to acknowledge Aleksandra Antevska and Dr. Thanh D. Do for their
mentorship. I would also like to thank the rest of the Do Lab for their support including
Amber Gray, Damilola Oluwatoba, Miranda Limbach, Sarah Hirschbeck, and Edward
Lindberg.

iii

ABSTRACT
We display the capabilities of our established liquid chromatography-ion mobility
spectrometry-mass spectrometry (LC-IMS-MS) workflow in the investigations of islet
chemistry at the sub-single-islet level. We begin by characterizing the structural differences
of Ins1 and Ins2 to present novel insights as to why their behaviors diverge. We then
examine the effects of the stress hormone corticosterone, the rodent equivalent of human
cortisol that is often used as a therapeutic, on pancreatic peptide hormone secretion. We
also uncover the molecular connection behind the inverse relationship between type 2
diabetes (T2D) risk and chronic migraine via the neuropeptides CGRP and PACAP. Lastly,
we apply our technique to the detection of posttranslational modifications (PTMs).
Through our studies, we elucidate how corticosterone-induced beta-cell
proliferation may lead to insulin resistance. Our results show that the level of amylin, a
peptide co-secreted with insulin from the beta-cells, increased significantly compared to
the control samples, correlating well with an increase in beta-cell population observed in
immunoassays. Furthermore, while the corticosterone-treated mice might produce a high
level of insulin due to the proliferation of insulin-positive cells, the hormones were quickly
degraded. Because the truncated form of insulin may not be as effective as the intact form,
our data help rationalize insulin resistance induced by corticosterone.
We show that alpha-CGRP remodels amylin fibrillization, a process implicated in
T2D. CGRP and/or amylin monomers reduce the secretion of both mouse Ins1 and Ins2
proteins, however, CGRP oligomers have a reverse effect on Ins1. Beyond the mechanistic
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insights, our data suggest that CGRP regulates insulin secretion and lowers the risk of T2D,
thus rationalizing how migraine might be protective against T2D.
We observe that PACAP-38 enhances Ins1 secretion under glucose stimulation yet
has no significant effects on Ins2 in-vitro. We address the need for future studies with
transgenic mice to determine if PACAP’s remodeling of islet morphology can serve
therapeutic purposes in T2D patients.
We demonstrate that DTIMS can capture important PTMs that can serve as
biomarkers—Asn deamination and IsoAsp formation. Finally, we use DTIMS analysis to
show that spontaneous cis/trans proline isomerization can occur under a different mobility
type.
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CHAPTER ONE
PANCREATIC ISLETS AND DISEASE
1.1 Pancreatic Islets of Langerhans
Islets of Langerhans are collections of endocrine cells that produce and secrete
signaling molecules called hormones. Islets are spread throughout the pancreas and play a
vital role in the homeostasis of many bio-physiological processes. They consist of five
main cell types—α-, β-, γ-, δ-, and ε-cells. α-cells produce the peptide hormone glucagon.
Glucagon is implicated in glucose homeostasis and increases blood glucose levels. To
achieve this, glucagon promotes glycogenolysis (the breakdown of glycogen to monomeric
glucose) and gluconeogenesis (the de novo synthesis of glucose) while also inhibiting
glycolysis (the breakdown of glucose for energy) and glycogenesis (the storage of glucose
into glycogen) [1]. β-cells produce insulin, whose functions oppose those of glucagon.
Insulin lowers glucose levels by inhibiting gluconeogenesis and glycogenolysis while
upregulating glycolysis and glycogenesis. Insulin also promotes protein synthesis and
lipogenesis—the synthesis of fatty acids and triglycerides from glucose [2]. γ-cells secrete
pancreatic polypeptide (PP). PP functions to reduce food intake, inhibit glucagon secretion,
and increase energy use [3, 4]. Somatostatin is secreted from δ-cells. Somatostatin inhibits
both insulin and glucagon release while also impeding β-cell proliferation—a process that
increases cell number [5]. Finally, ε-cells release ghrelin, a hormone that increases hunger,
inhibits insulin secretion, and reduces energy expenditure [6].

1

The percentage of each cell type compared to the overall number of endocrine cells
within islets differs between species. Human islets are comprised of 50-70% β-cells, 2040% α-cells, and less than 10 percent of γ-, δ-, and ε-cells [7]. Comparatively, laboratory
mouse (Mus musculus) islets contain 60-80% β-cells, 15-20% α-cells, <10% γ-cells and
<1% δ- and ε-cells [8]. Human and mouse islets also differ in cell arrangement,
morphology, and nerve fiber innervation patterns [7]. While these differences exist,
endocrine signaling pathways are highly conserved between mice and humans, and the
necessity of mouse models for human disease research is apparent.

1.2 Type 2 Diabetes as a Protein Misfolding Disease
Type 2 diabetes (T2D) is a degenerative metabolic disorder characterized by insulin
resistance and progressive β-cell dysfunction and/or death. T2D accounts for the vast
majority (~90%) of diabetes cases and affects more than 415 million people worldwide. Its
prevalence is expected to grow to ~642 million by the end of 2040 [9]. The aggregation of
human amylin (also islet amyloid polypeptide; hIAPP), has been implicated as the
causative agent of T2D [10]. Amylin is a 37-residue peptide that is synthesized in the
pancreas and co-released with insulin from pancreatic β-cells in a 1:100 ratio in healthy
patients [11]. Amylin is hydrophobic and contains an intramolecular disulfide bridge and
amidated C-terminus [12]. Amylin has physiological functions in glucose regulation via
gastric emptying, increasing satiety, and reducing gastric secretion [13]. It also inhibits
insulin secretion to lower blood glucose levels as well as prevents both the synthesis of
glycogen and glucose uptake [12].
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Amylin monomers are soluble and intrinsically disordered, meaning they lack a
well-defined structure in their native states. These monomers quickly aggregate at low
micromolar concentrations and accumulate into insoluble protein deposits called amyloid,
which is found in over 90% of T2D patients [14]. Normally, insulin binds amylin
monomers and inhibits their self-assembly and subsequent aggregation [15]. However,
under T2D pathology, initial glucose intolerance leads to increased insulin secretion, and
therefore, increased amylin secretion [16]. High levels of amylin lead to amylin nucleation
and subsequent aggregation. Amylin aggregation occurs via the conversion of helix-coil
conformations to helix-β-strand conformations in homodimers. These homodimers
propagate the β-sheet motif to other monomers [17]. The β-sheet motif allows for further
formation of oligomeric species and, ultimately, insoluble fibrils. Both oligomers and
fibrils induce cytotoxic effects, with oligomers being the primary culprits. Mechanisms of
amylin-induced toxicity include mitochondrial dysfunction, membrane pore formation and
dysfunction, formation of reactive oxygen species (ROS), initiation of apoptosis, DNA
damage, and islet inflammation [18]. All-in-all, excessive amylin aggregation results in the
early β-cell dysfunction and eventual β-cell death observed under T2D pathology.

1.3 Glucocorticoids and Diabetes Development
Cholesterol-derived steroid hormones called glucocorticoids (GCs) are synthesized
and released from the adrenal gland in response to emotional and physiological stress. GCs
are typically under hypothalamic-pituitary-adrenal (HPA) axis control [19]. GCs bind the
GC receptor, a nuclear receptor, and are implicated in a variety of physiological processes
such as immune response, metabolism, development, cognitive functions, and mood [203

23]. Administration of GCs is commonly used in the treatment of inflammation, cancer,
and autoimmune disease [24]. Despite its considerable therapeutic success, GC treatment
can result in side effects such as new-onset hyperglycemia. T2D patients are particularly
susceptible to a severe worsening of hyperglycemia [25]. Hyperglycemia involves an
excess of glucose in the bloodstream. Its onset can promote both insulin resistance and βcell dysfunction. Insulin resistance is characterized by the insensitivity of insulin in target
tissues, whereas β-cell dysfunction is more severe and displays impaired insulin secretion
[26]. Both insulin resistance and β-cell dysfunction further promote hyperglycemia and,
therefore, T2D. In addition to insulin, GCs can also affect glucagon, somatostatin, amylin,
and other islet peptides [27, 28].
Humans and mice utilize different GCs. Corticosterone is found primarily in
rodents, while in humans it is produced in low amounts (10-20-fold lower concentrations
than the primary GC secreted in humans, cortisol) [29-33]. Both cortisol and corticosterone
bind to the same mineralocorticoid receptors (MR) in the brain with high affinity, and the
glucocorticoid receptors (GR) with an approximately 10-fold lower affinity [34]. Both
molecules have 21 carbons; the only difference is an extra hydroxyl group at the 17th
carbon of cortisol (circled red in Figure 1). Various direct and indirect effects of
cortisol/corticosterone treatment have been reported with distinctions between acute and
chronic exposure [35]. Cushing syndrome, for example, is characterized by endogenous
hypercortisolism and can lead to T2D development [36]. Moreover, corticosterone
treatment has been shown to promote the early markers of β-cell proliferation that correlate
to insulin resistance and hyperinsulinemia without increasing total body mass [37]. Overall,
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Figure 1. Chemical structures of (A) cortisol and (B) corticosterone.
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stress is highly connected to metabolic processes through the secretion of GCs. As such,
the effects of GCs on the islet environment are important in understanding both how stress
can lead to disease development and how GC treatment can result in disastrous side effects
like diabetes.

1.4 Neuropeptides Link Type 2 Diabetes Risk with Chronic Migraine
Conditions
Migraine is a disabling neurovascular disorder affecting more than 12% of the
general population [38]. Migraine involves enhanced cortical excitability that leads to the
activation of the trigeminal sensory pathway and results in an inflammatory response that
causes pain [38]. Two epidemiological studies propose that patients with chronic migraine
have a much lower susceptibility to developing T2D [39, 40]. The inverse relationship
between the two diseases stems from a molecular connection mediated by migraineassociated neuropeptides that are either produced or have receptors in pancreatic cells.
There are a variety of these peptides including pain sensory (calcitonin gene-related
polypeptide [41]; CGRP, pituitary adenylate cyclase-activating polypeptide [42]; PACAP,
and substance P [43]; SP), sympathetic (neuropeptide Y [44]; NPY), and parasympathetic
(vasoactive intestinal peptide [45]; VIP) neuropeptides. CGRP and PACAP are both
implicated in migraine-associated vasodilation and nociception and have been reported to
modulate insulin secretion in pancreatic islets [46-49]. CGRP has been found to both
promote and inhibit insulin secretion, while PACAP stimulates insulin secretion in a
glucose-dependent way without inhibiting insulin sensitivity. Another neuropeptide, NPY
inhibits insulin secretion [50] with a feedback mechanism [51].
6

By evaluating the effects of these migraine-associated neuropeptides on the islet
environment, a better understanding of the connection between these diseases is achievable
and may lead to better therapeutic and preventative strategies. For example, the inhibition
of insulin secretion by CGRP and/or NPY would result in less amylin secretion. Decreased
amylin secretion would prevent excessive amylin aggregation and its associated
cytotoxicity. Furthermore, lower levels of circulating insulin are protective of T2D while
high levels of circulating insulin are a risk factor for insulin insensitivity and pancreatic
cancer progression [52, 53].
At first, the stimulation of insulin and amylin release by PACAP may seem
contradictory to the concept that chronic migraine is protective of T2D, however, PACAP
also stimulates the secretion of glucagon [54] and catecholamines [55]. The dual effect of
PACAP on elevating both glucagon and insulin levels allows for the increase in glucose
turnover without changing plasma glucose levels and inducing hyperglycemia [56].
Additionally, catecholamines mediate the increase of glucagon secretion while also
inhibiting insulin secretion, meaning the direct effects of insulin on the islet may be
suppressed by other mechanisms of PACAP [57]. Despite higher levels of insulin under
PACAP conditions, glucose elimination rates are unaffected [57]. PACAP also exerts
bidirectional effects on islet morphology depending on pathological status. For example,
PACAP significantly suppresses islet density and exhibits a reduction in islet mass in
transgenic mice with severe T2D with PACAP overexpression (A y/+:PACAP/+) compared
to Ay/+ mice [58]. The same study showed that PACAP may inhibit ductal islet neogenesis,
a mechanism implicated in the increased β-cell mass observed in T2D [58]. Alternatively,
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in T1D-induced mice, β-cell proliferation is observed under increased PACAP levels [59].
Increasing β-cell proliferation is proposed to counter the near-total loss of β-cells observed
under T1D pathology [60]. Finally, PACAP displays anti-diabetic effects through the
protection of β-cells against glucotoxicity, calcium toxicity, and lipotoxicity [59].

1.5 Project Goals
The overarching goals of this project are extensive. We aim to prove the robust and
reliable nature of our established LC-IMS-MS workflow [61] in detecting pancreatic
peptide hormones at the single-islet and sub-single-islet levels. We will apply this method
to observe the effects of stress-induced GC release and/or GC treatment on metabolism, as
well as to elucidate the molecular mechanism behind the inverse relationship between T2D
and chronic migraine. Particularly, the effects of acute corticosterone treatment on peptide
hormone secretion and enzymatic activity will be assessed to unravel the mechanisms in
which stress and/or steroid treatment may induce insulin insensitivity, β-cell dysfunction,
and eventual T2D. The link between chronic migraine and T2D will be explored through
the effects of migraine-associated neuropeptides, namely CGRP and PACAP, on
pancreatic islet chemistry. Along the way, we will determine the structural differences
between the previously uncharacterized mouse insulin 1 (Ins1) and insulin 2 (Ins2) proteins
and explore how differences in their primary sequences affect insulin aggregation
propensities and functions. Finally, the power of LC-IMS-MS in the analysis of biological
samples will be assessed with a separate peptide system and compared to a different IMSMS instrument type. Key posttranslational modifications will be explored in this peptide
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system which reveals novel abilities of drift tube (DT)IMS-MS to pinpoint asparagine
deamidation and subsequent isoaspartate formation to specific residue positions.
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CHAPTER TWO
APPROACH AND INSTRUMENTATION
2.1 Pancreatic Perfusion and Islet Isolation
For experiments involving mouse pancreatic islets, mouse treatment conditions
varied between projects and will be listed in each project’s representative section. Despite
this, a standardized pancreas perfusion and islet isolation method was performed, with the
steps outlined below.
To begin the pancreas perfusion, the desired mouse is anesthetized prior to cervical
dislocation. The surgical field is set up and the proper steps are taken to prepare the
pancreas for perfusion. A tiny hole is made in the common bile duct and a needle cannula
attached to the syringe of injection enzyme solution is inserted. 6 mL of prepared enzyme
injection solution is injected. The pancreas is then removed and placed in a Falcon tube
with ~10 mL enzyme injection solution. The serum is then processed, and the top layer is
extracted.
Digestion of the pancreas is then performed. The tube containing the pancreas and
enzyme is placed into a 37 °C water bath with oxygenation (95/5) for 5 minutes. Postoxygenation, the tube is placed in a water bath for 25 minutes and shaken every 5 minutes.
After digestion, the tube is removed from the water bath and a prepared cold quenching
buffer solution is added to stop the digestion of the enzyme. The solution is homogenized,
and undigested exocrine tissue is filtered out. The tube undergoes centrifugation at 1100
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RPM for 3 minutes at 4 °C. Finally, the supernatant is decanted, and excess liquid is
removed via gravity.
Extraction of islets is initiated with the addition of 7 mL of 25% polysucrose 400
Ficoll (Fisher 156328, MP Biomedicals), a hydrophilic polysaccharide utilized in gradient
centrifugation. Sequentially, 7 mL of 23%, 20%, and 11% Ficoll is added to separate the
sample into four distinct layers. The tube is centrifuged at 2100 RPM for 20 minutes. The
mouse islets are localized to the interface between the 20% and 11%, as well as between
the 23% and 20% Ficoll layers. Islets are removed and transferred to a Falcon tube
containing 30 mL quenching buffer before being centrifuged at 1100 RPM for 3 minutes
at 4 °C. Supernatants are then removed and washed with quenching buffer and another
round of centrifugation. New supernatants are removed and 10 mL of room temperature
RPMI 1640 with glutamine (Fisher 10040CV, Mediatech) are added to the pellet. All media
is then removed, and islets are placed in a tissue culture dish. An inverted microscope is
used to access the quality and purity of islets. Lastly, islets are placed in an incubator with
5% CO2 at 37 °C.
The day after isolation, islets are removed from the incubator. Islets are cleaned
until no ductal or exocrine tissue remains before they are counted and evenly distributed
into microcentrifuge tubes containing fresh media. The islets are subsequently stimulated
with IL-1B. First, 1 μL IL-1B is added to ~1 mL pure islet solution before incubation for
3 hours with 5% CO2 at 37 °C. After incubation, most of the media is removed and 300 μL
RLT (Qiagen 1015750) buffer is added. The islet solution is then placed in a -80 °C freezer.
Additional information can be found in a previous work [61].
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2.2 Liquid Chromatography-Ion Mobility Spectrometry-MassSpectrometry
The advent of ion mobility spectrometry-mass spectrometry (IMS-MS) has allowed
researchers and companies to apply the technique to a variety of fields such as explosives,
environmental analysis, food science, and (bio)chemical studies [62-65]. MS functions to
determine and quantitate analyte identities by their mass-to-charge ratios (m/z) [66]. IMS
enables the separation of gas-phase ions based on their charge, size, and shape to give
structural information about molecules [66]. The coupling of these techniques yields a high
resolving power proving useful to many diverse fields of research. Analyte ionization is a
key part of IMS-MS. Our primary instrument, the Agilent 6560 IMS-QTOF (Agilent, Santa
Clara), utilizes an electrospray ionization (ESI) source which transfers intact biological
samples into the gas phase [67]. ESI is considered a “soft” ionization method ideal for
biological samples. When the aqueous sample is introduced to the ESI-jet stream source, a
high voltage is applied to the emitter needle. The liquid is eluted as a fine mist of charged
droplets. This is called the Taylor cone. Solvent molecules subsequently evaporate from
the charged droplets. Charge repulsion promotes the ejection of smaller charge droplets
until there is only one ion per droplet. Ions are then pulsed into the ion mobility cell that is
under an electric field and filled with inert gas, typically helium (He) or nitrogen (N2). Ions
in the drift cell collide with the chosen buffer gas and separate based on their charge, size,
and shape. Upon reaching the end of the drift cell, ions move through a quadrupole timeof-flight (Q-TOF) mass spectrometer before reaching the detector. This results in arrival
time distribution (ATD) data that yields information on the size and shape of analytes. Ion
12

abundance can also be obtained from ATD data. The Q-TOF separates ions based on their
m/z ratios. The detector allows for the generation of a mass spectrum that pairs each m/z
ratio to an ion and its relative intensity. Lastly, a collisional cross section (CCS) can be
determined for analytes. CCS enables further identification of analytes across various ion
mobility instruments. CCS represents the shape of an ion of a specific compound in a
particular buffer gas environment. CCS (σ) is related to the ion’s reduced mobility (K 0)
which is calculated using arrival times and the Mason-Schamp equation [68]:

𝜎𝑒𝑥𝑝 ≈

3𝑧𝑒 1
2𝜋
√
16𝑁0 𝐾0 𝜇𝑘𝐵 𝑇

Equation 1: Mason-Schamp Equation
where z is the charge of the ion, e is the elementary charge, N 0 is the gas number density
of the drift-gas, Ko is the reduced mobility, μ is the reduced mass of the ion and drift-gas,
𝑘𝐵 is the Boltzmann constant, and T is the temperature of the drift gas. CCS is a powerful tool, as
it can be compared across multiple measurement modalities including nuclear magnetic resonances
(NMR), x-ray crystallography, circular dichroism (CD), computational modeling, and electron
microscopy [69].
A liquid chromatography (LC) system can be coupled to the Agilent 6560 IMS-MS
instrument. LC can further identify analytes in complex solutions based on their retention time—
the time it takes for a sample to elute from the column. This property depends on the polarity of the
analytes in the sample. Our workflow utilizes an Agilent 1260 Infinity LC with a 2.1x50 mm Zorbas
Extended C18 reverse-phase column (Agilent, Santa Clara).
Drift Tube IMS-MS Method
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DTIMS experiments were performed on an Agilent 6560 IMS-QTOF (Agilent
Technologies, Santa Clara). Samples were ionized with an ESI source and ions were pulsed
through a nitrogen-filled drift cell (3.94 Torr) in a multifield experiment. Upon exiting the
drift cell, ions were guided through the QTOF mass spectrometer by a hexapole ion guide.
Data were collected in positive polarity with ∆V = 1490, 1390, 1290, 1190, and 1090 V.
ATDs and mass spectra were analyzed with Agilent IM-MS Browser software (v.10.0).
CCSs were determined using Equation 1.
LC-IMS-MS Method
Per each run, 4.0 μL of each sample was injected into a 2.1 x 50 mm Zorbas
Extended C18 reverse-phase column (Agilent, Santa Clara). The mobile phase consisted
of an aqueous solution of 0.1% formic acid in LC-grade water (solvent A) and acetonitrile
(solvent B). The mobile phase gradient is as follows: 98% solvent A for 3 minutes, 80%
solvent A (minutes 3-5), 65% solvent A (minutes 5-18), 50% solvent A (minutes 18-23),
25% solvent A (minutes 23-26), 10% solvent A was held for 2 minutes and then followed
by a rise to 98% (minutes 35-40) and kept for 5 minutes (minutes 40-45) for column
calibration. The column was set to 40 °C.

2.4 LC-IMS-MS vs. Traditional Immunoassays
Traditionally,

researchers

use

immunoassays

like

the

enzyme-linked

immunosorbent assay (ELISA) to measure insulin secretion. ELISA functions by
exploiting the reactions between antigens and antibodies. First, antigens are put into a solid
phase and allowed to react with antibodies. The addition of a second, enzyme-labeled
antibody detects this reaction [70]. When using chromogenic substrates that induce color
14

changes in the particular enzymes added, color development arises where the antigen is
present and can is detected and quantified using a microtiter plate reader [70].
There are two major advantages of our LC-IMS-MS workflow to ELISA methods.
First, ELISA requires ~30 islets to measure secreted insulin levels. Our LC-IMS-MS
workflow can reliably detect insulin levels at the sub-single-islet level. In our sub-singleislet experiments, a single islet is suspended in 50 μL of solvent. Only 4 μL of the islet
solution is injected into the instrument, meaning we measure approximately 1/10 th of a
single islet which includes ~150 cells. We can detect heterogeneity within islet cell
populations by collecting multiple technical replicates of these ~150 cells from a single
islet. Furthermore, we can utilize multiple islets from the sample animal per experiment.
This limits variations between animals and limits animal-related costs.
Secondly, ELISA is unable to distinguish between isoforms of insulin in animals
possessing more than one insulin gene. Mice, for instance, have a two-gene system
encoding mouse insulin 1 (Ins1) and mouse insulin 2 (Ins2). Our LC-IMS-MS method can
distinguish between mouse Ins1 and Ins2 and has shown these proteins have different
structures and actions [61]. We propose the ability/inability to distinguish these isoforms
is vital to research efforts that aim to correlate mouse insulin functions to those of human
insulin functions. These features highlight the advantage LC-IMS-MS has over traditional
methods of islet chemical analysis.

2.4 Trapped Ion Mobility Spectrometry-Mass Spectrometry
Trapped ion mobility spectrometry (TIMS)-MS is a mobility type that can achieve
a much higher resolving power (R ~200) than the drift tube (DT)IMS instrument (R ~40)
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[71, 72]. The TIMS instrument employs an electric field to hold ions stationary against a
moving gas [69]. This setup is the inverse of the DTIMS instrument. Despite their
differences, TIMS operates under the same physics as DTIMS within the drift cell, meaning
ATD and CCS data can still be obtained accurately. ESI, among other ionization methods,
can be applied to the TIMS instrument, similar to the DTIMS instrument.

2.5 Circular Dichroism
Circular dichroism (CD) is used to investigate the secondary structure of proteins
and peptides. CD arises from the unequal absorption of left-handed and right-handed
circularly polarized light [73]. These two polarized waves can be separated by prisms or
devices that use Pockel’s effect. Asymmetric molecules differentially absorb left- and
right-handed circularly polarized light, which is detected by CD instruments. Each
secondary structural element—β-sheet, loop, α-helix, etc.—has a unique CD spectrum.
This enables researchers to predict the secondary structure of uncharacterized peptides and
explore conformational changes due to aging, heat, interactions, and mutations [73]. In this
study, we will use CD to probe differential conformations of Ins1 and Ins2 to observe how
those structures change over time.

2.6 Scanning Transmission Electron Microscopy
Scanning transmission electron microscopy (STEM) is a tool used to view samples
at the atomic level, enabling microstructural characterization. STEM focuses a high energy
beam of electrons, at a high angle unlike the perpendicular angle in TEM, from an electron
gun onto a small probe at the specimen plane. This happens while the instrument is pulled
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under a vacuum. The electron probe is then scanned across the specimen. Transmitted
inelastically scattered electrons, as opposed to elastically scattered electrons in TEM, are
collected by the detectors for each point [74]. The result is the formation of Z-contrast
images based on the angular distribution of transmitted electrons where the scattering angle
depends on the mean atomic number Z of the specimen [75].
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CHAPTER THREE
CHARACTERIZATION OF MOUSE INSULIN 1 AND INSULIN 2
Unlike humans, mice have a two-gene system that encodes two insulin proteins—
insulin 1 (Ins1) and insulin 2 (Ins2). The Ins2 gene is the orthologue of human insulin,
while the Ins1 gene is a retrogene that originated from a partially processed Ins2 mRNA
strand that was reverse-transcribed and incorporated into the murine genome [76]. It is
proposed that the Ins1 retrogene was positively selected for in mice and its preservation in
the genome served as an evolutionary advantage during ancient times due to the lack of
available food resources [76]. Ins1 was shown to be more sensitive to glucose stimulation
than Ins2 [77], making it advantageous under scant food conditions. However, as food
became more abundant, Ins1 left mice with a greater susceptibility to T1D development.
Ins2 was also positively selected for, most likely due to its ability to protect mice from
T1D. Unlike most retrogenes, Ins1 contains regulatory regions similar to those of Ins2.
mRNA expression levels of Ins1 and Ins2 are similar (57:43% of the total insulin mRNA)
[77]. However, Ins1 and Ins2 have diverged functions in metabolism. For instance, a study
on non-obese diabetic (NOD) mice lines showed that male NOD mice with only one copy
of Ins1 develop type 1 diabetes (T1D) before reaching 10 weeks of age, and female NOD
mice with only one copy of Ins1 have a high prevalence of T1D and islet inflammation
(insulitis). Alternatively, male and female NOD mice with only one copy of Ins2 exhibit
normal insulin levels and do not experience T1D pathologies [78]. Unlike Ins1 NODknockout (KO) mice, Ins2 NOD-KO mice displayed lower levels of insulin content than
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wild-type (WT)-NOD mice in both males and females [78]. These results suggest that Ins1
may be a defective gene due to the lack of compensatory mechanisms.
Apart from diverged genetic regulation and functions, Ins1 and Ins2 also differ in
structure. The insulin genes encode preproinsulin which includes the N-terminal signaling
peptide, A-chain, B-chain, and connecting peptide (C-peptide). Preproinsulin is then
cleaved to proinsulin consisting of the A-chain, B-chain, and C-peptide. Here disulfide
bonds form between the A-chain and B-chain at residues A7-B7 and A20-B19. An
additional interchain disulfide bond is created at A6-A11. Proinsulin is cleaved at either
side of the C-peptide leaving the mature insulin protein containing only the A-chain and
B-chains with the disulfide bonds intact. The C-peptides differ at three residues, and Ins1
displays two gaps in the sequence compared to Ins2. In mature insulin, Ins1 and Ins2 differ
at two residues in the B-chain—positions B9 and B29. Ins1 incorporates a proline at B9
and a lysine at B29, whereas Ins2 has a serine at B9 and a methionine at B29. Note, that
human insulin includes a serine at B9 and a lysine at B29. Mouse and human insulins differ
at one position in the A-chain (AspA4 in mice and GluA4 in humans). The variation in
primary sequences between Ins1 and Ins2 results in structural differences that may lead to
differential aggregation propensities and diverged molecular actions. Figure 2 compares
human insulin, mouse Ins1, and mouse Ins2 sequences. Red stars indicate residue
differences in the B-chains, lines indicate disulfide bonds, and the B9-23 segment is
indicated by bold and italic font. The blue VEALYL sequence highlights the
amyloidogenic region. Dissimilar to biological assays, our LC-IMS-MS workflow can
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Figure 2. Comparison of the primary sequences of human insulin and mouse Ins1
and Ins2.
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distinguish between Ins1 and Ins2 in isolated mouse islets, making it a powerful tool for
their characterization. Our data on isolated islets show that Ins2 is degraded more readily
than Ins1, as seen in Figure 3. Intact Ins2 levels are lower than intact Ins1 levels and
truncated forms of Ins2 are prominent. We hope to characterize Ins1 and Ins2, for the first
time, with LC-IMS-MS to explain degradation patterns observed in mouse islets. We focus
our attention on Ins1 and Ins2 B-chains, as the only differences in the primary sequences
occur there. We also investigate the B9-23 segments, which have been demonstrated to
elicit different immune responses [79]. Ins1 B9-23 was suggested to be diabetogenic, while
Ins2 B9-23 protects against spontaneous diabetes in NOD mice [79]. The proline in Ins1
B9-23 may be the driving factor behind these results. Furthermore, the B9-23 segments are
particularly prone to aggregation and include the amyloidogenic region—VEALYL [80].
The effects of proline substitution within the B9-23 segment will also be explored.

3.1 Materials and Methods
The Ins1 and Ins2 synthetic B-chains used for this study were synthesized by
LifeTein, LLC and used without any further purification. Ins1 and Ins2 B9-23 peptides
were synthesized with the help of Dr. Kristi Cantrell and Ethan Hawke from Westmont
College. The peptides were pretreated with hexafluoroisopropanol (TCI America).
Aliquots of the peptide stocks were left to evaporate in a desiccator overnight. All insulin
B-chains and B9-23 segments were reconstituted in LC-grade water (VWR) in 20 mM
ammonium acetate buffer, pH = 6.8, for final peptide concentrations of 10 𝜇M. All DT
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Figure 3. 3D plot of the ion abundances of intact Ins1 (red), intact Ins2 (blue), and
truncated Ins2 peptides (yellow, green, and purple).
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IMS-MS and LC-IMS-MS experiments were carried out according to the methods outlined
in Chapter 2.2.
Far-UV Circular Dichroism
Ins1 B9-23 and Ins2 B9-23 were diluted to a concentration of 100 μM in 10 mM
sodium phosphate, pH = 7.0. The samples were filtered using a 0.20 μm, 4 mm Titan
syringe regenerated cellulose filter to remove insoluble materials. Samples were diluted to
100 μM using the extinction coefficient for the tyrosine residue (e275 = 1420 cm-1 M-1). The
absorbances were measured on a Thermo Electron Corporation Nicolet Evolution 200 UVVisible Spectrometer. CD data were collected in a Jasco J-810 CD spectrometer. The CD
measurements were collected at 1 nm intervals from 260 to 190 nm with a 4 s response
time and a 1 nm bandwidth. All spectra were collected at 22 °C in a 1 mm quartz cuvette.
Fifteen scans were collected, the data were averaged, a baseline generated from a sample
containing only the solvent was subtracted from the averaged scans, and the curves were
baseline corrected. Spectra were taken of samples quickly following their preparation and
incubated in a 37 °C water bath for 1 week before collecting the final spectra to test for βsheet formation.
Scanning Transmission Electron Microscopy
Ins1 B9-23 and Ins2 B9-23 peptides were diluted to a concentration of 100 μM in
10 mM sodium phosphate, pH = 7.0. Samples were stored in a water bath at 37 °C for 1.5
weeks. The samples were then spun down for fifteen minutes at 10,000 rpm. The Ins B923 samples formed a pellet upon centrifugation, and a pellet was not observed with the fulllength B chain peptides. Samples (5 μL) were applied to a glow discharged, 400-mesh,
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carbon-coated support film and stained with 1% uranyl acetate. Images of fibrils at a
magnification of 21,000X and 137,200X were recorded using an FEI Tecnai F30 scanning
transmission electron microscope (STEM) operated at 300 kV and equipped with a Gatan
charge-coupled device (CCD) digital micrograph.

3.2 Ins2 Adopts a More Compact Conformation than Ins1
We began by performing an LC-IMS-MS analysis of the synthetic Ins1 B-chain.
The acquired chromatogram displays two distinct peaks indicating unique different
features, as seen in Figure 4. The mass spectrum of the Ins1 B-chain (z = +5) in each LC
feature shows that the monoisotopic m/z ratio shifts to the left by ~2 Da. This mass shift is
attributed to the oxidation/reduction of an intramolecular disulfide bond between the
cysteine residues at B6 and B19. The LC peaks were labeled either oxidized (with disulfide
bond) or reduced (without disulfide bond). The mass shift of ~2 Da stems from the loss of
two hydrogens when the disulfide bond is oxidized. To confirm the oxidation/reduction
reaction was indeed taking place, H2O2 was added to samples in a 1:10 H2O2:Ins1 B-chain
ratio. H2O2 has the propensity to exert both oxidizing and reducing actions. Figure 5
displays the results of time-course H2O2 experiments in which the addition of H2O2 initially
(t = 1 hour) shifts the sample towards the reduced form without the disulfide bond before
rearranging into the oxidized form at t = 24 and t = 68 hours. Peptide aging in the absence
of H2O2 shifts the B-chain to the oxidized form. The Ins2 B-chain mass spectrum also
displays the ~2 Da mass shift indicating disulfide bond formation. Note that even in
oligomers, disulfide bonds were identified as intramolecular, not intermolecular, bonds.
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Figure 4. LC chromatogram of Ins1 B-chain showing disulfide bond formation with
associated mass spectra.
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Figure 5. Time-course LC experiments of Ins1 B-chain with H2O2.

26

The presence of these non-native disulfide bonds may affect insulin B-chain aggregation
and structure. Turning to mobility data, the collected CCSN2 values of oxidized Ins1 Bchain and Ins2 B-chain were 782.37 Å2 and 741.70 Å2 (z = 4) respectively. CCSN2 values
of reduced Ins1 B-chain and Ins2 B-chain were 898.60 Å2 and 817.85 Å2 (z = 4). ATDs
were obtained with LC-IMS-MS, as seen in Figure 6, which shows that Ins2 B-chain has a
smaller arrival time (z = 4) in both oxidized and reduced forms than Ins1 B-chain. These
results indicate that Ins2 B-chain is more compact and folded than Ins1 B-chain.
Synthetic Ins1 and Ins2 B9-23 segments were also evaluated with LC-IMS-MS in
similar conditions to insulin B-chains. Figure 7 represents the mass spectra, ATDs, and 2D
plots of the B9-23 segments (z = 2). The presence of a non-native intermolecular disulfide
bond is indicated by a mass shift of ~2Da. Because the B9-23 segments contain only one
cysteine residue per monomer, we observe two monomers linking covalently to form a
dimer. The CCSN of Ins1 B9-23 was found to be 431.1 Å2 (z = 2). The CCSN2 of Ins2 B923 was 428.3 Å2 (z = 2). The main conformer in Ins1 B9-23 arrives at 28.80 ms, while the
primary Ins2 B9-23 conformer arrives at 28.67 ms. These results indicate that, as expected,
Ins2 B9-23 is more compact compared to Ins1 B9-23. The observation that both Ins2 Bchain and Ins2 B9-23 adopt more compact conformations than Ins1 B-chain and Ins1 B923 correlates well with our data on mouse islets that show mature Ins2 also adopts a more
compact and folded conformation. We speculate that Ins2 is better at retaining its native
folded state than Ins1 given that most proteins start to unfold/denature as the charge state
increases.
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Figure 6. ATDs of Ins1 and Ins2 B-chains with reduced and oxidized disulfide bonds
(z = +4).
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Figure 7. IMS-MS characterization of Ins1 and Ins2 B9-23
segments.
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3.3 Ins1 Oligomerizes More Readily than Ins2
Direct infusion IMS-MS on synthetic insulin B-chains show that oligomerization
is not apparent at t = 0 but occurs by t = 96 hours. Figure 8 includes mass spectra of Ins1
B-chain (top) and Ins2 B-chain (bottom) with normalized intensity. Peaks are indicated
with the oligomer state/charge ratios (n/z). Monomers (n/z = 1/4, 1/3, 1/2), dimers (1/2,
2/3), trimers (3/5, 3/4), and tetramers (2/3) are all observed in both Ins1 B-chain and Ins2
B-chain. Ins1 B-chain portrayed a greater propensity to form oligomers than Ins2 B-chain,
as evidenced by the higher intensity for dimeric and tetrameric species in Figure 8.
Similar to the B-chains, direct infusion IMS-MS on the synthetic insulin B9-23
segments shows that oligomerization is apparent at t = 7 days. Figure 7 shows that the mass
spectra, ATD, and 2D plot are more intense for the Ins1 B9-23 dimer than for the Ins2 B923 dimer (both at n/z = 1/2), indicating Ins1 B9-23 oligomerizes more readily, much like
the full Ins1 B-chain. Figure 9 displays the mass spectra of Ins1 and Ins2 B9-23 dimers
(n/z = 2/3) at t = 7 days, showing the dimer is more intense in Ins1 B9-23 than Ins2 B9-23.
Our results show that both Ins1 B-chain and Ins1 B9-23 oligomerize more readily
than Ins2 B-chain and Ins2 B9-23. Mature human insulin dimerization is thought to
proceed through interactions between newly formed β-strands of natively disordered
residues (B24-B28) between two monomers [81]. Van der Waals contacts between
hydrophobic residues of the B-chain α-helix and β-strand are also thought to be implicated
in this process. The 3D structure of the human insulin dimer is shown in Figure 10. The
proline present in Ins1, but not Ins2, may drive the differences in oligomerization observed
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Figure 8. Mass spectra indicating oligomeric species in Ins1 and Ins2 B-chains.
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Figure 9. Mass spectra of Ins1 B9-23 and Ins2 B9-23 showing the dimer (n/z = 2/3).
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Figure 10. 3D structure of the human insulin dimer and pH = 2 (PDB = 1GUJ) [81,
82].
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in our experiments. In human insulin dimers, SerB9 has been shown to interact with
GluB’13 and TyrB’16 of the opposite monomer [83]. Furthermore, SerB9 is implicated in
a pathway leading to insulin dimer dissociation [83]. ProB9 in Ins1 may form stronger
contacts with residues of the opposite monomer as well as disrupt the dimer dissociation
pathway. Proline is more hydrophobic than serine and can form van der Waals with
hydrophobic residues within the hydrophobic core of the dimer. Furthermore, if ProB9 can
interact with TyrB’16, favorable CH/π interactions can form between the two residues [84].
Our direct infusion IMS-MS results show that the residue difference in the B9
position can alter oligomerization rates, a cytotoxic pathway. We incorporated circular
dichroism (CD) and scanning transmission electron microscopy (STEM) to look at
aggregation propensities. Figure 11 represents CD data of Ins1 B9-23 and Ins2 B9-23
obtained at t = 0 days and t = 7 days after incubation. Both peptides display primarily
random coil conformations at t = 0 days but shift to β-sheet conformation at t = 7 days. The
α-helix to β-sheet transition is implicated in the insulin fibrillization mechanism [85].
Fibrillization is a cytotoxic pathway in which oligomers are disassembled into
monomers that become partially misfolded, undergo the transition to a β-sheet
conformation, and aggregate into highly stable rod-like structures. Figure 12 presents TEM
images of Ins1 B9-23 and Ins2 B9-23 segments incubated for 1.5 weeks. Both Ins1 and
Ins2 B9-23 segments show substantial fibrillization, however, Ins1 B9-23 was observed to
form fibrils more extensively across the sample. Again, the proline at residue B9 may alter
the 3D structure of the peptide and be implicated in the fibrillization process.
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Figure 11. CD data of Ins1 B9-23 and Ins2 B9-23.
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Figure 12. TEM images of Ins1 B9-23 and Ins2 B9-23.
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3.4 Non-Enzymatic Peptide Cleavage Gives Insight into Ins1 and Ins2
Degradation Patterns
Despite using ESI, a “soft” ionization method that is thought to minimize
fragmentation, we observe considerable non-enzymatic peptide cleavage (fragmentation)
in LC-IMS-MS experiments on synthetic insulin B-chains without utilizing collisioninduced dissociation (CID) capabilities. ESI fragmentation proceeds through the mobile
proton model which states that when protons are added during ESI, they can travel across
the peptide backbone and attach to amide nitrogen [86]. This allows for nucleophilic attack
by the C-terminally located carbonyl oxygen on the carbonyl carbon and leads to either a
bx-ion or a yz-ion and a neural fragment as seen in Figure 13 [87].
The general assumption is that peptide bonds from a more folded region are
protected from fragmentation, while peptide bonds from unstructured regions are more
susceptible to it. Typically, the weakest peptide bonds in a particular peptide are affected
by fragmentation. Our data shows substantial fragmentation only under LC-IMS-MS
conditions and not when samples are directly infused into the IMS-MS instrument. This
implies the LC system denatures the peptides. It has been reported that reverse-phase LC
disrupts hydrophobic interactions in peptides due to the hydrophobicity of the matrix [88].
This would disrupt the secondary structure of the peptides and allow for fragmentation near
aromatic/hydrophobic residues. Figure 14 shows the mass spectra obtained using LC-IMSMS of aged Ins1 and Ins2 B-chains with reduced disulfide bonds and normalized intensity.
Ins1 B-chain displays a multitude of very low-intensity fragments, whereas Ins2 B-chain
shows more intense fragments. This tells us that Ins2 B-chain has a higher propensity to
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Figure 13. Peptide fragmentation mechanism.
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Figure 14. Mass spectra of Ins1 and Ins2 B-chains showing fragmentation.
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fragment and may include weaker peptide bonds than Ins1 B-chain. Looking at the
fragmentation pattern in Figure 15, we can see that most fragmentation for the reduced
form of Ins1 B-chain occurs in the middle of the peptide while most fragmentation in the
reduced form of Ins2 B-chain takes place towards the C-terminal. When we look at the
structure of human insulin in Figure 16, we can see that the A-chain interacts with the
middle region of the B-chain. We propose the A-chain protects the weakest peptide bonds
in Ins1 through these interactions. On the other hand, the C-terminal portion where the
weakest bonds of Ins2 are located is highly exposed. Correlating the fragmentation patterns
with the 3D structure allows us to rationalize the increased degradation of mature Ins2
compared to mature Ins1 seen in Figure 3.

3.5 Conclusions
This is the first study to characterize the differences in structure and
oligomerization propensities of mouse Ins1 and Ins2. We investigated synthetic insulin Bchains and B9-23 segments with LC-IMS-MS. We conclude that a) Ins2 B-chain is more
compact than Ins1 B-chain, b) Ins1 oligomerizes more readily than Ins2, c) Ins2 B-chain
has a higher propensity to fragment and may be a less stable peptide than Ins1 B-chain, and
d) fragmentation patterns of the B-chains provide a rationale for the increased degradation
of Ins2 observed in biological samples. Overall, we demonstrate that Ins1 and Ins2 have
different structures and functions. Given this, distinguishing between mouse Ins1 and Ins2
is vital for making conclusions about human insulin behavior. Our LC-IMS-MS workflow
has proven to be robust in that it can easily distinguish between Ins1 and Ins2, unlike
traditional methods.
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Figure 15. Fragmentation patterns of Ins1 and Ins2 B-chains.
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Figure 16. 3D structure of human insulin (PDB 3I40) [82, 89].
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CHAPTER FOUR
THE EFFECTS OF ACUTE CORTICOSTERONE TREATMENT ON
MOUSE PANCREATIC PEPTIDE HORMONES PROBED AT THE
SUB-SINGLE-ISLET LEVEL
4.1 Materials and Methods
Pancreatic Perfusion and Islet Isolation
Twelve 8-week-old male C57BL/6J mice (stock #000664, The Jackson Laboratory,
Bar Harbor, Maine) were obtained and allowed to acclimate to animal facility light (12 h
light/12 h dark) and temperature (22 ± 1°C) conditions for two weeks. Mice had access to
standard chow and drinking water ad libitum until they reached 10 weeks of age. Then,
mice were evenly distributed between treatment or control drinking water groups
randomly. Treatment group mice were given drinking water containing 100 μg/ml
corticosterone in 1% ethanol. Control group mice were given drinking water containing
1% ethanol. Upon reaching 12 weeks of age, the mice were euthanized via CO 2
asphyxiation and cervical dislocation. Pancreatic perfusion was performed, and islets were
isolated in the method explained in Chapter 2.1.
All live animal procedures were approved by the University of Tennessee
Institutional Animal Care and Use Committee. After islet isolation, islets were incubated
at 37°C and 5% CO2 for 24 h in RPMI + D-glucose. After incubation, islets were transferred
into Eppendorf tubes containing 5% MeOH/0.1% formic acid solution. This study used six
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mice for two sets of experiments. First, three islets each from three corticosterone-treated
mice were used. Secondly, one islet each from three control mice was used.
Drift Tube IMS-MS
All chemicals utilized were reagent grade and were used without further
purification. Rodent amylin peptides were obtained from AnaSpec (California, USA) at
98% purity. Glucagon peptides were obtained from Millipore Sigma. Peptide powders from
both amylin and glucagon peptides were pretreated with hexafluoroisopropanol (TCI
America) and solvents were left to evaporate in a desiccator overnight. Prior to IMS-MS
experiments, peptide stock solutions were prepared by reconstituting the lyophilized
peptides in LC-grade water (Mercedes) and diluting it to 10 μM in a buffer of 20 mM
ammonium acetate (VWR), pH = 6.8. Drift tube IMS-MS experiments were carried out
according to the method outlined in Chapter 2.2.
LC-IMS-MS
Isolated islets were placed in a 50 μL solution of 5% MeOH/1% formic acid. Three
technical replicated were obtained from each sample, with two consecutive blank injections
between each sample for column cleaning. LC-IMS-MS experiments were run according
to the method outlined in Chapter 2.2.

4.2 Sampling of Pancreatic Hormones from Single Mouse Islets
Our established LC-IMS-MS workflow allows for the accurate detection of various
peptide hormone levels from approximately one-tenth of a single islet as described in
Chapter 2.4. This allows for the collection of multiple technical replicates on the same
islet sample and the investigation of several conditions on the same animals. Here, we
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compared pancreatic hormone levels in control and corticosterone-treated male mice.
Corticosterone treatment in this study was carried out for two weeks and is considered to
be acute. Ins1, Ins2, glucagon, amylin, and truncated insulin and amylin peptides were
detected in islet samples and their abundances were compared per treatment group. Tables
1 and 2 summarize the LC-IMS-MS characterization of peptide hormones from control and
corticosterone-treated mice.
Figure 17A shows an extracted, partial LC chromatogram of a single islet from a
control mouse. The retention times of major islet hormones were annotated. Figure 17B
displays the mass spectra and ATDs of the peptide hormones. Ins1 was detected at four
different charge states which were identified unambiguously with the isotope spacings with
a mass accuracy of -2.58 ppm. Ins2 was detected at the same four charge states with a mass
accuracy of 0.69 ppm. To verify the mass spectral peaks of endogenous Ins1 and Ins2, we
performed glucose-stimulated insulin secretion (GSIS) experiments on batches of 10
control mouse islets. Islets were treated with both 3 mM and 16 mM glucose. The media
after each treatment was collected and analyzed with LC-IMS-MS. Secreted insulin
accounts for less than 5% of the total insulin within islets. GSIS experiments on three
batches of islets showed that when islets were treated with 16 mM glucose, a higher level
of mouse insulin was detected than when treated with 3 mM glucose, as seen in Figure 18.
This data is consistent with the expected behavior of glucose-responsive β-cells.
Using IMS-MS, Ins1 and Ins2 structures can be compared via ion mobility and CCS
measurements. Note, that the three disulfide bonds within Ins1 and Ins2 are assigned based
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Table 1. LC-IMS-MS characterization of pancreatic peptide hormones in control
mice.
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Table 2. LC-IMS-MS characterization of pancreatic peptide hormones in mice
under corticosterone treatment.
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Figure 17. Extracted chromatogram (A), mass spectra (B), and ATDs (C) showing
pancreatic peptide hormones.
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Figure 18. Summary of GSIS experiments.
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on the crystal structures of porcine [89] and human [90] insulins, but since there is no
crystal structure of Ins1, we cannot eliminate the possibility that the disulfide bonds of Ins1
were scrambled. Previously, we have established that the experimental CCS of Ins2 is in
good agreement with human insulin [61]. Furthermore, we showed that Ins2 adopts a more
compact and folded conformation than Ins1 does. This suggests that Ins2 is better at
retaining its native folded state than Ins1 and stems from the structural differences in the
B-chain, as discussed in Chapter 3.2.
Glucagon was detected at two charge states with a mass accuracy of 5.03 ppm.
Figure 17C shows the ATD of endogenous glucagon in which two primary, well-resolved
features are seen—one at 25.39 ms and the other at 26.54 ms. LC and direct infusion IMSMS experiments were performed on synthetic glucagon. Synthetic glucagon displayed
similar mobility features to endogenous glucagon at 25.56 ms and 26.86 ms, as seen in
Figure 19. The experimental CCSHe of synthetic glucagon were 620 Å2 and 645 Å2. CCSHe
of endogenous glucagon were 616 Å2 and 641 Å2. Glucagon CCS is reported here for the
first time.
Amylin was detected at one charge state with a mass accuracy of -4.33 ppm. Our
amylin assignment was confirmed with experiments on synthetic mouse amylin peptides.
Experiments of both endogenous and synthetic amylin display two mobility features at
25.55 ms and 26.62 ms with corresponding CCSHe of 618 Å2 and 638 Å2. Helium CCSs
were reported here to compare them to another study in which our CCS values of
endogenous amylin are in strong agreement with (619 Å 2 and 644 Å2) [91]. In addition to
intact amidated amylin, the peaks labeled red in the amylin mass spectrum of Figure 17B
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Figure 19. Characterization of synthetic glucagon.
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represent amylin(2-37). The truncated amylin peptide was observed at three different
charge states. The robust nature of our workflow is apparent in our detection of Ins1, Ins2,
glucagon, and amylin. While insulin can be detected by MSI experiments on rodent
pancreatic tissues or by high-throughput single-cell analyses, only one insulin isoform
(Ins1) is often reported. Furthermore, in a healthy pancreatic islet, the ratio of insulin to
amylin is approximately 100:1. Since insulin concentration in a single islet is
approximately ~1 mM (~10 ng in 1.0 nL volume), an analytical technique with a limit of
detection (LOD) of femtomole or better would easily detect insulin from a single cell (~1
pL). However, given amylin concentration is 100 times lower (~10 µM), detecting this
important peptide would require a LOD of attomole or better. Therefore, the advantages of
our method include shorter acquisition time and improved analyte coverage at the expense
of tissue contexts and individual cell identities [92].

4.3 Effects of Acute Corticosterone Treatment on Insulin Chemistry
Probed at the Single-Islet Level
Our experiments showed an inhibitory effect on glucagon within islets of mice
treated with corticosterone. This correlates with another study that demonstrated islet
incubation in 50 nM corticosterone for two hours corresponded to a reduction in glucagon
following low glucose stimulation [93]. All other peptides excluding the truncated amylin
(residues 2-37) and one truncated form of Ins2 [A+B(1-23)], which, like glucagon, were
not observed in all islets of both conditions, were analyzed with a one-way ANOVA to
determine the statistical significance of our data. This was followed by a Tukey test
between the control and treatment conditions. Figure 20 shows the statistical analyses.
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Figure 20. Statistical analysis of the effects of corticosterone treatment on pancreatic
hormones.
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We observed that while both intact Ins1 and Ins2 levels dropped in corticosterone-treated
mice, only the Ins2 levels dropped significantly compared to the control mice. The opposite
trend was observed with the putative truncated insulin peptides, in which all but the Ins2
A+B(1-29) peptide increased significantly. Amylin is co-secreted with insulin from
pancreatic β-cells and its levels were analyzed under corticosterone treatment. We
observed that amylin levels were significantly increased only in corticosterone-treated
mice.
These observations have interesting implications for understanding acute
glucocorticoid treatment and the effects of stress on the islet environment. First, the
differential effects of corticosterone on Ins1 and Ins2 indicate the need to differentiate these
proteins in biological samples to reliably make conclusions on human insulin behavior.
Here, only Ins2—the orthologue of human insulin—levels decreased significantly under
corticosterone treatment. Furthermore, the enzymatic hydrolysis products of Ins2 increased
significantly and will be discussed thoroughly below. Finally, the significant increase of
amylin levels in corticosterone-treated mice implies that either the healthy ratio of
insulin:amylin (100:1) was impaired or the level of amylin increased proportionally with
an increase in insulin production. Similar results are reported when a synthetic GC,
dexamethasone is used [94-96]. Specifically, both the plasma amylin level and amylin
secretion from isolated pancratia were increased in dexamethasone-induced insulin
resistant (IR) rats. These findings suggest that GC administration may aid in amylin release.
The human amylin version is amyloidogenic and has long been linked to T2D. Studies have
shown that amylin fibrils have been found in the pancreas of 95% of T2D patients [97, 98].
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The amylin aggregates are toxic to the pancreatic β-cells. Therefore, our experiments here
provide a molecular basis linking a high level of corticosterone/cortisol with T2D in
humans.

4.4 Ins2 is Enzymatically Degraded at a Much Faster Rate than Ins1
Our LC-IMS-MS workflow was able to detect multiple truncated Ins1 and Ins2
peptides. This truncation occurs towards the C-terminal of the B-chains and is due to
enzymatic hydrolysis. We observe only a single truncated Ins1 peptide—Ins1 A+B(1-24).
Alternatively, we detect five truncated Ins2 peptides including Ins2 A+B(1-23), A+B(124), A+B(1-25), A+B(1-28), and A+B(1-29). The differential cleavage patterns are most
likely due to the differences in secondary structures between Ins1 and Ins2, specifically
within the B-chains. The cleavage patterns are indicated by arrows in Figure 21. The
retention times, observed masses, and mass accuracy of the truncated Ins1 and Ins2
peptides are displayed in Table 1. We note that the MS ions we detected correspond to the
complete peptides (with NH2 N-terminus and COOH C-terminus) and not MS fragments
(b- and y-ions). This excludes the possibility that the peptide cleavages were due to MSinduced in-source fragmentation. Furthermore, the truncated peptides have distinct
retention times from the intact proteins, indicating that they existed in solution. Lastly,
different rates of degradation were found for Ins1 compared to Ins2, suggesting that the
truncated forms are formed due to enzymatic activities rather than MS-induced processes.
Furthermore, Grasso and co-workers observed a similar enzymatic cleavage pattern in
bovine insulin: A+B(1-24), A+B(1-25) to name among others [99]. Note that the bovine
insulin has a serine at the B9 position much like Ins2. Many other studies show that insulin55

Figure 21. Peptide sequences and cleavage patterns.
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degrading enzyme (IDE) has a high affinity to hydrolyze insulin between the two
phenylaniline residues at B24 and B25. Congruently, our data show that both the A+B(124) Ins1 and Ins2 truncated peptides are the highest in intensity in the islets of the
corticosterone-treated mice.
Each truncated insulin peptide that was detected in the corticosterone-treated mice
was also identified in the control samples, except for Ins2 A+B(1-23). As stated in Chapter
4.3, the levels of all but one truncated insulin peptide were significantly increased in the
corticosterone-treated mice while intact Ins1 and Ins2 levels dropped, as seen in Figure 20.
These results may stem from differential binding propensities of Ins1 and Ins2 to the IDE.
IDE is a zinc metallothiolproteinase and serves as the major endopeptidase for insulin
degradation in the pancreas. IDE also binds and cleaves other peptide hormones like
glucagon [100], amylin [101], and somatostatin [102], albeit with a much lower affinity
[103]. A study by Wei-Jen Tang and co-workers on human insulin showed that residues
B1-B4 and B13-B20 convert from an α-helix into a β-strand conformation and form βsheets with IDE strands β-12 and β-6, respectively [104]. However, residues B6-B12 were
not observed in the crystal structure, and the impacts of S9P (Ins2 → Ins1) on the IDE
binding mechanisms have not yet been explored. We rationalize that given Ins1 includes a
proline at residue B9 compared to serine at B9 in Ins2 and human insulin, the
disproportionate hydrolysis of Ins2 in islets may be due to structural changes in Ins1 that
disfavor IDE binding compared to Ins2. This is supported by the role of proline in the
disruption of secondary structures. Additionally, the same study found that peptides that
do not have a significant positive charge at the C-terminal and avoid the repulsion from
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IDE-C are better substrates. By looking at the Ins1 and Ins2 peptide sequences, we see that
Ins2 includes a neutral methionine residue towards the C-terminal, whereas Ins1 has a
positively charged lysine residue.
As mentioned above (and seen in Figure 17B), we were also able to detect a
truncated form of amylin as well (2-37). Since IDE has an approximately 4-fold greater
affinity for insulin than for amylin, the amylin degradation will be proportionally impaired
[101]. This increased amylin production coupled with lower levels of degradation may
allow for sufficient accumulation of amylin, which could lead to islet amyloid formation
[101].
Overall, our results indicate that corticosterone actions increase the enzymatic
activity of endopeptidases like IDE within mouse islets. Previous studies on similar mice
showed that after two-week exposure to corticosterone, a high level of serum insulin was
observed together with an increase in insulin-positive cells. It was suggested that during
this period, corticosterone promoted β-cell proliferation. From the same study, it was
shown that insulin sensitivity was reduced, evident by the high level of serum glucose
compared to control mice. Our data here provide a reasonable explanation. Despite
increased insulin production in corticosterone-treated mice, the mature insulins are more
readily degraded leading to high abundances of truncated and biologically less-active
peptides. Eventually, the β-cells produce more insulin leading to reduced insulin
sensitivity. Because Ins2 is more prone to IDE degradation than Ins1, this leads to a
condition where intact Ins1 becomes dominant. Essentially, the mice would behave more
similarly to those with only the Ins1 gene. As mentioned above, transgenic mice without
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the Ins2 gene develop diabetes as early as 10-weeks old. The IDE resistance property of
Ins1, compared to Ins2, may explain why Ins1 is a defective form of insulin and why the
diabetes risk is increased with this form.
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CHAPTER FIVE
ELUCIDATING THE MOLECULAR CONNECTION BETWEEN
TYPE 2 DIABETES AND CHRONIC MIGRAINE PART I: CGRP
Calcitonin gene-related peptides (CGRPs), just like amylin, are part of the
calcitonin gene family. CGRP exists in two major isoforms—α-CGRP and β-CGRP. αCGRP is expressed in the CNS and PNS, whereas β-CGRP is expressed in the enteric
nervous system [105]. Both isoforms of CGRP are released from sensory nerves [106] and
δ-cells within pancreatic islets [107]. CGRP has been implicated in both inhibiting [46,
108] and stimulating [109] insulin secretion. Here, our LC-IMS-MS workflow will be
applied to single isolated mouse islets to observe the effects of CGRP on mouse Ins1 and
Ins2. Furthermore, we will investigate how CGRP affects amylin fibrillization and amylinassociated cytotoxicity. Note, that three residues are different in mouse α-CGRP compared
to the human peptide, as seen in Figure 22.

5.1 Materials and Methods
Chemicals were purchased and used without further purification. Human amylin
and human α-CGRP peptides were purchased from AnaSpec (California, USA) at 98%
purity. Peptide powders were pretreated with hexafluoroisopropanol (TCI America).
Solvents were left the evaporate in a desiccator overnight. Prior to IMS-MS analysis, stocks
of each peptide were prepared by reconstituting the lyophilized peptide in LC-grade water
(Honeywell) and diluting it to 10 μM in a buffer of 20 mM ammonium acetate (VWR), pH
= 6.8. The amylin:CGRP mixture was prepared by mixing the two peptide stocks in a 1:1
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Figure 22. Primary sequences of pancreatic peptides.
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ratio and diluting the solution with 20 mM ammonium acetate to the final concentration of
each peptide of 5 μM. For the peptides containing ZnCl2, we used 50:50 methanol:H2O in
place of ammonium acetate.
Mouse Islet Culturing and Harvesting
Six 10-week-old male C57BL/6J mice (stock #000664) were ordered from the
Jackson Laboratory (Bar Harbor, Maine) and allowed to acclimate to the animal facility
conditions on a 12 h light cycle at 22 ± 1 °C. The mice were provided standard chow and
drinking water ad libitum until they reached 12 weeks of age. At 12 weeks of age, the mice
were euthanized via CO2 asphyxiation followed by cervical dislocation. All procedures
were approved by the University of Tennessee Institutional Animal Care and Use
Committee. Additional details regarding pancreatic perfusion and islet isolation can be
found in the ESI [61]. Following isolation, the islets were incubated at 37 °C and 5% CO2
for 24 h in RPMI + D-glucose. After the 24-hour incubation, the islets were individually
pipetted into Eppendorf tubes containing the blank solvent, solutions of individual
peptides, or a mixture of the peptides.
Here we used a total of six mice for two sets of experiments. In the first set of
experiments (3 mice), islets from the same mouse, except for those used as controls, were
incubated with fresh amylin, fresh CGRP, or a fresh mixture of amylin and CGRP. We
used at least 3 islets from different mice per peptide condition. Because our LC-IMS-MS
workflow was optimized for sub-single-islet measurements, we can test multiple
conditions on the same mouse, and obtain multiple (at least three) technical replicates from
a single islet. In the second set of experiments (3 mice), we followed the same procedure
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as above. The only difference is that the islets were incubated with 4-day-old amylin,
CGRP, or the 1:1 mixture.
DTIMS-MS and LC-IMS-MS
DTIMS experiments were performed on an Agilent 6560 IMS-QTOF (Agilent
Technologies, Santa Clara). Samples were ionized with an ESI source and ions were pulsed
through a helium-filled drift cell (3.94 Torr). Upon exiting the drift cell, ions were guided
through the QTOF mass spectrometer by a hexapole ion guide. Data were collected in
positive polarity with ∆V = 890, 790, 690, 590, and 490 V. Additional instrument
parameters can be found in a previous paper [61]. ATDs and mass spectra were analyzed
with Agilent IM-MS Browser software (v.10.0). CCSs were determined using Equation
1—the Mason-Schamp equation.
Stocks of amylin and CGRP were prepared as previously described and diluted with
a 5% MeOH/0.1% formic acid solution to a final concentration of 10 μM. The
concentration of each peptide in the amylin:CGRP mixture was 10 μM. Aliquots of 50 mL
of each peptide solution (amylin, CGRP, and amylin:CGRP) were placed into Eppendorf
tubes, wherein single islets were manually placed. Two sets of peptide solutions were used:
a fresh solution, where the peptide solutions were prepared approximately one day before
acquiring the islets and contains primarily peptide monomers, and then an “aged” solution,
where peptide solutions were left at room temperature for four days before islet acquisition
and consist primarily of peptide oligomers. The “aged” solution was characterized with
IMS-MS to determine the relative ratios of oligomers to monomers. This was used to
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evaluate the effect of oligomers on the same islet system. LC-IMS-MS analysis was carried
out according to Chapter 2.2.

5.2 CGRP Disrupts Amylin Fibrillization
We utilize IMS-MS, TEM imaging, and cell viability assays in the characterization
of CGRP and amylin aggregation, an event that is cytotoxic to cells. IMS-MS shows that
amylin has a higher propensity to form oligomers or aggregates than CGRP. We carried
out additional studies with the addition of ZnCl2, as Zn2+ plays a vital role in the islet
environment and has previously been shown to inhibit amylin fibrillization at low
extracellular concentrations [110, 111] yet promote aggregation at high intracellular
concentrations [111]. IMS-MS shows that when Zn or the Zn(H2O)5 adduct complex with
amylin, the β-hairpin conformation of amylin is promoted and stabilized [61]. The βhairpin conformation is implicated in the fibrillization of amylin. The same studies were
performed on CGRP. Much like amylin, the addition of the Zn or the Zn(H2O) 5 adduct to
CGRP mediates the transition to the β-hairpin conformation. However, this transition
occurs to a lesser extent, and the α-helix (predicted with REMD) prevails as the primary
conformation [61]. The propensity for CGRP to maintain the α-helix motif prevents its
aggregation.
TEM imaging shows that amylin forms fibrils with and without the addition of
ZnCl2, whereas CGRP does not form aggregates or fibrils in either condition [61].
Interestingly, TEM shows that CGRP prevents amylin fibrillization when the two are
placed in a 1:1 mixture. Cell viability assays using cultured β-cells exposed to amylin,
CGRP, or the mixture were utilized to determine the cytotoxicity of the aggregates. The
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release of an intracellular enzyme marker of death, adenylate kinase, was investigated. No
significant direct cytotoxicity on β-cells was observed in any of the conditions [61]. This
implies a non-direct mechanism of amylin-associated toxicity through inflammation that is
mediated by islet resident macrophages [112].

5.3 Effects of CGRP and Amylin on Insulin Secretion
LC-IMS-MS analysis of isolated mouse islets allowed us to distinguish and detect
Ins1 (observed mass of 5799.668 Da, 0.276 ppm difference from theoretical mass) and Ins2
(observed mass of 5793.5974, 2.261 ppm difference from theoretical mass) across multiple
charge states. CCS values for Ins1 and Ins2 at z = 4 are 753 Å2 and 783 Å2 in helium and
902 Å2 and 936 Å2 in nitrogen respectively. CCS values for Ins1 and Ins2 have not been
reported before; however, our observed values agree well with the CCS of the human
insulin monomer at z = 4 (772 Å2) [113].
The structural differences between intact Ins1 and Ins2 can be seen in the 2D plots
of Figure 23, which shows that Ins2 adopts an additional conformation that Ins1 does not.
This conformation has a smaller arrival time, indicating it is more folded and compact.
These structural differences served as the basis for the investigations of Ins1 and Ins2 Bchains in Chapter 3.
Figure 24 displays the statistical analysis, comprised of a one-way ANOVA
analysis followed by a Tukey test between each condition, of Ins1 and Ins2 levels in control
islets and islets incubated in either amylin, CGRP, or a mixture of amylin and CGRP.
Experiments were performed in either fresh (A & C) or aged (B &D) media. Fresh media
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Figure 23. 2D plots of arrival time vs. m/z of Ins1 and Ins2 at z = +6. Adapted from
Gray et al. Chem. Sci. 2021.
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Figure 24. Comparisons of insulin secretion obtained from islets. Adapted from
Gray et al. Chem. Sci. 2021.

67

is thought to contain CGRP monomers, whereas aged media consists of more CGRP
oligomers. The presence of monomers or oligomers is confirmed by LC-IMS-MS analysis
[61]. Ins1 and Ins2 levels are differentially affected. For Ins1, levels decrease significantly
in fresh media of all conditions and increase significantly after aged CGRP incubation. The
observed dual effect of CGRP on insulin secretion is founded on the behavior differences
between CGRP monomers and oligomers. For Ins2, all three conditions inhibit its secretion
in both fresh and aged samples.
Ultimately, CGRP alone can effectively reduce the secretion of Ins2, the human
orthologue, but is less effective on Ins1. Given the fact that amylin is co-secreted with
insulin from β-cells, lowering insulin secretion is a viable strategy to prevent amylin
aggregation and the progression of T2D. Additionally, CGRP hinders the fibrillization of
amylin, a mechanism implicated in T2D. Lastly, CGRP is shown to be nontoxic to β-cells.
Ultimately, CGRP serves as a primary component in the molecular connection behind the
inverse relationship between T2D risk and chronic migraine conditions, and exogenous
CGRP treatment could be an effective strategy to combat T2D.
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CHAPTER SIX
ELUCIDATING THE MOLECULAR CONNECTION BETWEEN
TYPE 2 DIABETES AND CHRONIC MIGRAINE PART II: PACAP
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a vasodilator that
plays a role in migraine pathophysiology through its actions within the trigeminovascular
system as an activator of the nociceptive pathway and its modulation of neurotransmission
and neuro-inflammation in other areas of the brain [114]. PACAP exists in two bio-active
forms—PACAP-38 (the most abundant form) and the result of its internal cleavage,
PACAP-27—and binds the G-protein coupled receptors (GPCRs) PAC1, VPAC1, and
VPAC2, all three of which are expressed in pancreatic islets [38]. PACAP has many
different functions in various organ systems such as the urinary, reproductive,
gastrointestinal, endocrine, central nervous, and peripheral nervous systems [38]. In islets,
PACAP signaling results in the activation of adenylate cyclase which increased cyclic
AMP (cAMP) levels to activate protein kinase A (PKA) [115]. PKA promotes the
exocytosis of insulin-containing granules and the opening of L-type calcium channels.
PACAP binding to PAC1 also activates phospholipase C (PLC) which releases calcium
from calcium stores to increase cytosolic calcium levels. Lastly, PACAP elevates
cytoplasmic sodium levels. Increases in intracellular calcium and sodium, coupled with
activation of PKA, enhance insulin secretion in a glucose-dependent manner [115]. As
mentioned in Chapter 1.4, the physiological role PACAP plays is quite complex. In this
study, we will characterize PACAP using IMS-MS for the first time. Furthermore, because
PACAP is often co-localized with CGRP [116], we will determine whether the two
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peptides form oligomeric complexes. We will explore the idea that PACAP might complex
with amylin, similar to CGRP as discussed in Chapter 5.2. Finally, we will investigate the
in-vitro effects of PACAP on glucose-stimulated Ins1 and Ins2 secretion from pancreatic
islets. Note, that the primary sequence of PACAP is identical in mice and humans (Figure
22).

6.1 Material and Methods
Chemicals were purchased and used without further purification. The PACAP-38
peptide was purchased from GenScript (USA) and used without further purification.
Peptide powders were pretreated with hexafluoroisopropanol (TCI America). Solvents
were left the evaporate in a desiccator overnight. Prior to IMS-MS analysis, a stock solution
of PACAP was prepared by reconstituting the lyophilized peptide in LC-grade water
(Honeywell) and diluting it to 10 μM in a buffer of 20 mM ammonium acetate (VWR), pH
= 6.8.
Mouse Culturing and Harvesting and GSIS Protocol
Four 10-week-old male C57BL/6J mice (stock #000664) were ordered from the
Jackson Laboratory (Bar Harbor, Maine) and allowed to acclimate to the animal facility
conditions on a 12 h light cycle at 22 ± 1 °C. The mice were provided standard chow and
drinking water ad libitum until they reached 12 weeks of age. At 12 weeks of age, the mice
were euthanized via CO2 asphyxiation followed by cervical dislocation. All procedures
were approved by the University of Tennessee Institutional Animal Care and Use
Committee. Additional details regarding pancreatic perfusion and islet isolation can be
found in Chapter 2.1. Following isolation, the islets were incubated at 37 °C and 5% CO2
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for 24 h in RPMI + 11.1 mM D-glucose. After the 24-hour incubation, the islets were
transferred to a clean plate with 5 mM glucose in RPMI media for 18 hours. Then islets
were transferred to an Eppendorf tube containing 0.1 mL of 3 mM glucose in HBSS. After
1 hour, the supernatant was removed and measured for secreted insulin. The same islets
were then incubated in 0.1 mL of 15 mM glucose in Hank’s balanced salt solution (HBSS).
After 1 hour, the supernatant was removed again and measured for secreted insulin. Islets
were partitioned into tubes containing 1, 10, or 30 islets. Islets were placed into either
control or PACAP treated (10 μM) groups. Three technical replicated were obtained from
each sample, with two consecutive blank injections between each sample for column
cleaning. LC-IMS-MS experiments were run according to the method outlined in Chapter
2.2. DTIMS-MS experiments on PACAP were carried out according to the method outlined
in Chapter 2.2.

6.2 IMS-MS Characterization of PACAP-38 and its Interactions with
CGRP and Amylin
Using IMS-MS, PACAP-38 is detected at seven different charge states (see Figure
25), which were identified unambiguously with isotopic spacing. The most intense peak
was m/z = 907.3132 (charge = +5, △ppm = 17.63). Mobility data of PACAP shows 2
distinct features at 28.85 ms and 30.09 ms (z = +5). The CCSN2 of these conformers
are 1070.59 Å2 and 1138.46 Å2 respectively. The main conformer of PACAP has a
quicker arrival time and smaller CCS, indicating it is more folded than the other
conformer.
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Figure 25. Characterization of PACAP.

72

Next, we investigate PACAP oligomerization and its complexation with CGRP and
amylin. Figure 26 shows the mass spectra of samples containing either PACAP and CGRP
or PACAP and amylin. PACAP displayed low levels of dimerization at n/z = 1/2 and 2/5.
CGRP formed both dimers and trimers (n/z = 1/2 and 3/5). PACAP:CGRP 1:1 complexes
were found at charge states +4 and +5. Amylin formed dimers and trimers at n/z = 2/5 and
3/7. Various complexes of amylin and PACAP were observed, including 1:1, 1:2, and 1:3
PACAP:Amylin. Like CGRP, PACAP interacts readily with amylin in solution. Studies
with TEM will be conducted in the future to determine if PACAP exhibits prevention of
amylin fibrillization, as was seen with CGRP.

6.3 PACAP Exhibits a Small Effect of Ins1 Secretion In-Vitro
Our GSIS protocol allows us to measure secreted versus overall insulin levels in
isolated mouse islets using LC-IMS-MS. Measurements of secreted insulin were obtained
after stimulation with 15 mM glucose. The amount of secreted insulin is about 1.5 ± 0.04%
of the total insulin, as seen in Figure 27. With this in mind, we can apply this method to
measure the effects PACAP has on secreted and total insulin levels. A one-way ANOVA
was performed to determine the statistical significance of our data. This was followed by a
Tukey test between the control and treatment conditions. The statistical analysis is
summarized in Figure 27. Our data show that treatment with 10 μM PACAP only has a
significant effect on secreted Ins1 levels, but not Ins2 levels, in which PACAP increased
Ins1 secretion. This data is interesting, as we initially expected Ins2 levels to increase with
PACAP exposure as well. As discussed previously, PACAP actions are seemingly quite
complex. In the future, we hope to conduct studies using LC-IMS-MS to study the in-vivo
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Figure 26. PACAP oligomerization and complexation with CGRP and Amylin.
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Figure 27. Statistical analysis of PACAP GSIS experiments.
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effects of PACAP with transgenic mice to give us a better idea of the ramifications PACAP
has on the islet environment. We also hope to identify PACAP’s effects on other pancreatic
hormones like amylin and glucagon. Lastly, we plan to explore the changes in morphology
that PACAP exerts on β-cells using microscopy-guided single-cell profiling MS
(MicroMS).
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CHAPTER SEVEN
LC-IMS-MS FOR BIOCHEMICAL ANALYSIS OF
POSTTRANSLATIONAL MODIFICATIONS
7.1 Non-Enzymatic Posttranslational modifications and Peptide Cleavages
Observed in Peptide Epimers
Posttranslational modifications (PTMs) allow organisms to maintain cellular
homeostasis by modulating protein function and stability. PTMs regulate protein turnover,
localization, enzymatic activity, protein-protein interactions, and expression levels [117122]. More than 600 different PTMs are currently listed in the UniProt database [123]. A
posttranslational modification is executed through the addition, removal, exchange, and
rearrangement of functional groups to amino acid side chains [124] and the peptide
backbone [125]. These modifications occur both spontaneously and through enzymatic
activity. Given the vital role of PTMs in the cellular environment, they serve as biomarkers
for many disease states including cancer [126], neurodegeneration [127], aging [128],
diabetes [129], and cardiovascular disease [130].
Traditional

methods

of

PTM

identification

include

isotopic

labeling,

immunochemistry, and amino acid analysis [131]. Recent advances in MS have proven
useful for PTM quantitation and have led to the identification of many new PTMs. MS has
many advantages over traditional techniques due to increased sensitivity and the ability to
identify PTMs in complex solutions, study volume-limited samples, identify specific PTM
sites, and discover novel PTMs [132]. Coupling IMS to MS techniques further enhances
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their capabilities to identify PTMs that are isomeric/isobaric through the additional
separation of ions in the gas phase based on their electrophoretic mobility in buffer gas
[133].
This work utilizes both trapped ion mobility spectrometry (TIMS)-MS and drift
tube IMS (DTIMS)-MS to explore PTMs in the pleurin peptide system. Pleurin peptides
are found endogenously in the central nervous system (CNS) of Aplysia californica and
contain D-amino acids in the N-terminal regions. Recent studies show differential
isomerization of pleurin peptides in specific regions of A. californica’s CNS and
demonstrate the relevance of L- to D-residue isomerization [134, 135]. We follow up these
studies by exploring three important PTMs that can occur in the absence of enzymes—
proline cis/trans isomerization, asparagine (Asn) deamidation to aspartate (Asp), and Asp
isomerization to IsoAsp. We direct our focus to the Plrn2 peptides, namely, L-Plrn2, D3Plrn2, and P12A-Plrn2 (the sequences are shown in Figure 28) to capture these PTMs and
determine whether they are biological, or instrument driven. This contribution will speak
to the capabilities of TIMS and DTIMS in the study of PTMs.

7.2 Material and Methods
Peptide Sample Preparation
All samples of the Plrn2 peptides used for this study were purchased from
GenScript and used without any further purification. The peptides were pretreated with
hexafluoroisopropanol (TCI America). Aliquots of the peptide stocks were left to evaporate
in a desiccator overnight. The three Plrn2 peptides were then reconstituted in LC-grade
water (VWR) in 20 mM ammonium acetate buffer at pH 6.8, or phosphate-buffered saline
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Figure 28. Peptide sequences of Plrn-2 peptides.
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(PBS), for final peptide concentrations of 10 𝜇M. All DT IMS-MS and LC-IMS-MS
experiments were carried out according to the methods outlined in Chapter 2.2.

7.3 P12A Mutation Confirms Cis/Trans Proline Isomerization in TIMS
that is not observed in DTMS
Cis/trans proline isomerization can occur through peptidyl-proline isomerases
[136] or spontaneously. However, spontaneous isomerization happens on the order of
microseconds to seconds which is slower than protein folding [137]. Proline is unique
compared to other amino acids in that there is a similar steric clash in both the cis and trans
conformations of peptide bonds, resulting in a potential energy difference between isomers
of only ~2.1 kJ/mol, compared to ~10.5 kJ/mol in other non-proline peptide bonds, and a
transition barrier of ~54.4 kJ/mol [138]. Like non-proline-containing peptide bonds, there
is still a preference for the trans proline isomer [139]. The cis conformer is rare in native
proteins, yet can be found more frequently in the denatured state [140]. Cis/trans proline
isomerization is implicated in protein folding dynamics [139, 141] cell signaling [142], and
the regulation of protein stability [143].
Figure 29A shows the ATD obtained with the TIMS instrument of the P12A-Plrn2
monomer (z = +2). As seen from the primary sequences in Figure 28, P12A-Plrn2 has
alanine in place of proline. A single intense peak is observed in the ATD, indicating one
major conformer present. The inset of Figure 29A shows the mass spectrum of the
monomer, whereas Figure 29B shows the ATD obtained with the TIMS instrument of the
L-Plrn2 monomer (z = +2). Two distinct peaks are observed in the ATD, indicating
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Figure 29. Mobility data collected with the TIMS instrument of P12A-Plrn2 (A), LPlrn2 (B), and the DTIMS instrument of P12A-Plrn2 (C), and L-Plrn2 (D).
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1

two conformers in the sample. The less intense peak has a higher reduced ion mobility (𝐾 ),
0

representing a more elongated 3D structure than the more intense first peak. The first peak
has similarly reduced ion mobility to the peak in Figure 29A. The inset of Figure 29B
shows the mass spectra of the two conformers which verify they share the same m/z ratio.
The disappearance of the second peak in the P12A-mutated peptide indicates that the
conformers in the L-Plrn2 ATD represent the cis/trans isomerization of the proline.
Additional ion mobility measurements were acquired using a DTIMS instrument to
determine whether the cis/trans proline isomerization observed in Figure 29B was
biological or instrument-driven. Figure 29C shows the ATD obtained with the DTIMS
instrument of the P12A-Plrn2 monomer (z = +2). A single intense peak is observed, which
was similarly observed in the TIMS data. The ATD obtained with the DTIMS instrument
of the L-Plrn2 monomer (z = +2) is shown in Figure 29D where a single major peak is
observed, indicating only one conformer is present in the sample.
These results indicate that the DTIMS instrument did not capture cis/trans proline
isomerization. Even though the TIMS instrument has higher resolving power (R typically
around ~200 compared to ~40 in DTIMS) [71, 72], the DT instrument should have
sufficient resolution to distinguish these peaks given the large differences in CCS data.
While TIMS is an efficient method to investigate the conformational dynamics of
biomolecules and “soft” settings can be employed to study native folding [144], structural
rearrangements have been observed when higher DC voltages or longer measurement time
scales are utilized [145]. The successive build-up of internal energy over time allows ions
to overcome isomerization barriers [145] which is most likely the case with the TIMS data
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on Plrn2 in which an accumulation time of 350 ms was used. “Softer” TIMS parameters
include accumulation times as low as ≤ 10 ms [144] but decrease resolving power at the
same time [146].

7.4 Non-Biological Asn Deamidation and IsoAsp Formation
Since Plrn2 peptides contain two asparagine (Asn) residues in their sequence, we
investigated the ability of the DTIMS instrument to capture Asn deamidation, a PTM that
is occurring here in the absence of a biological environment. Samples of L-Plrn2 were run
through the DTIMS instrument via direct infusion as soon as the sample was prepared (t =
0 days; fresh), stored at ~4 °C, and re-ran about five months later (t = 159 days; aged). The
2D plots of m/z vs. arrival time of L-Plrn2 (z = +2) are shown in Figure 30. The 2D plot of
the fresh sample shows a single distinct peak that represents one major species. Evidence
of a second species arises in the aged sample 2D plot that coincides with a mass shift of
+0.984 Da which denotes Asn deamidation [147].
Asn deamidation is a spontaneous PTM that proceeds non-enzymatically through
either direct hydrolysis or a succinimide intermediate. Initially, Asn cyclizes to the gemhydroxylamine tetrahedral intermediate resulting from the nucleophilic attack of the (N +
1) residue’s amide nitrogen to the amide carbon of the Asn side chain [148].
Deammoniation of the gem-hydroxylamine intermediate forms succinimide. Figure 31
shows that the succinimide intermediate is detectable in the mass spectrum of L-Plrn2 at z
= +2 as evidenced by a mass shift of -17.02 Da. LC-MS/MS confirmed the identification
of the succinimide intermediate (Figure 32). The succinimide ring is then hydrolyzed
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Figure 30. 2D plots and mass spectra of fresh and aged L-Plrn2.
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Figure 31. Mass spectrum displaying the detection of the succinimide intermediate
in red.
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Figure 32. MS/MS of succinimide intermediate.
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resulting in Asp formation [147]. Depending on which carbonyl of the ring is hydrolyzed,
Asp or IsoAsp is produced with IsoAsp typically predominating in a 3:1 ratio [149].
IsoAsp formation was further investigated with LC-IMS-MS experiments. Figure
33A shows the LC chromatograms of the L-Plrn2 peptide run at t = 0 days and t = 2 days.
Only one peak is observed in the t = 0 days sample, whereas three distinct peaks are
observed in the t = 2 days sample. The peaks from left to right were identified as the native
asparagine-containing peptide, IsoAsp-containing peptide, and Asp-containing peptide,
respectively. Figure 33B presents the 2D plots of m/z vs. drift time for Asn, IsoAsp, Asp,
and succinimide-containing peptides (z = +2). Figure 33B shows that Asn deamidation
causes the peptide structure to become more compact, while the isomerization to IsoAsp
loosens the peptide structure. The mobility of the succinimide intermediate is similar to
that of Asp and IsoAsp, which is expected given its similar molecular geometry.
Using low-energy collision-induced dissociation (CID) through ESI-MS/MS,
diagnostic b- and y-type ions have been identified to distinguish Asn, Asp, and IsoAsp
[150]. The internal rearrangement of IsoAsp yields [bn-1 + H2O] and [𝑦"𝜄−𝑛+1 − 46] ions
[151]. Figure 34 shows the MS/MS data for P12A-Plrn2. The b-ions were detected at m/z
772, 829, and 944 indicating that both Asn7 and Asn9 can be deamidated. The presence of
the [y8+-46] and [b7++18] ions but not [y6+-46] and [b9++18] ions show that only the first
Asn (N7) is deamidated and subsequently isomerized into IsoAsp. IsoAsp formation tends
to occur more readily in flexible protein regions and when the C-terminal residue is glycine,
which is why we only see IsoAsp in the 7th position and not the 9th position [152]. Asn
deamidation and IsoAsp formation are associated with many biological and pathological
87

Figure 33. A) LC chromatographs of L-Plrn2 at t = 0 and t = 48 hours. B) 2D plots
of observed peptides.
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Figure 34. MS/MS of deamidated L-Plrn2.
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processes and act as a molecular clock [153]. Asn deamidation is implicated in age-related
diseases such as cataracts [154, 155], macular degeneration [156], osteoarthritis [157], and
neurodegeneration [158]. Asn deamidation also has roles in type 2 diabetes [159],
autoimmune disease progression [160], gene regulation [161], protein stability [162], and
cancer [163]. Given this, Asn deamidation and IsoAsp formation serve as biomarkers for
many of these diseases. Our work shows that the DTIMS instrument can effectively capture
both Asn deamidation and its subsequent formation of IsoAsp. Furthermore, the precise
location of Asn deamidation and IsoAsp formation can be probed with MS/MS, and we
found that IsoAsp formation was more likely to occur at the Asn residue between two
glycine residues (N7) compared to a glycine and histidine residue (N9).

7.5 Non-Enzymatic Peptide Cleavage in Pleurin Peptides
Like with the insulin peptides in Chapter 3, extensive non-enzymatic peptide
cleavage was observed in LC-IMS-MS experiments of the Plrn2 peptides despite the use
of a “soft” ionization method. The mass spectrum obtained from the LC-IMS-MS
experiments is shown in Figure 35A The peaks corresponding to the y-ions, y11, and y12,
are intense, with

the

y12 ions

corresponding to (d)YTTGNGNHYPRI and

YTTGNGNHYARI being the most intense. This indicates that the bond most susceptible
to hydrolysis is between Phe2 and Tyr3, the two residues that exist in both L- and Dconfigurations [135]. Figure 35B shows the 2D plot and mass spectrum of the y11 ion. The
presence of two distinct features with a mass shift of +0.984 Da indicates that
fragmentation is not induced through Asn deamidation. Similar results are obtained for L-
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Figure 35. A) Mass spectrum of LC-IMS-MS data of L-Plrn2. Labeled y-ions
provide evidence for non-enzymatic peptide cleavage. B) 2D plot and mass spectrum
of the y11 ion.
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Plrn2 in the TIMS instrument but not for direct infusion DTIMS-MS experiments.
Furthermore, similar fragmentation patterns (between hydrophobic and aromatic residues)
are captured when other pleurin peptides (Plrn1 and Plrn3) are analyzed with the TIMS
instrument [134].
Contamination of the LC column with proteases such as chymotrypsin from prior
experiments was proposed to explain this cleavage. However, proteases tend to have
increased specificity for L-amino acids and do not readily cleave D-amino acids due to a
lack of interactions in the active site [164]. There was not a significant difference between
the fragmentation rates of L-Plrn2 and D3-Plrn2, indicating that the observed cleavage is
not due to enzymatic activity.
As stated in Chapter 3.4, the mobile proton model states that in MS, protons move
across the peptide backbone and can lead to non-enzymatic cleavage via nucleophilic
attack resulting in b- and y-ions [165]. The general assumption is that peptide bonds of a
folded and protected region are less likely to be cleaved than those from unstructured or
flexible regions. Given that extensive fragmentation is only observed in LC experiments
and not direct infusion, the LC component of the instrument might denature the peptides.
It has been reported that reverse-phase LC disrupts hydrophobic interactions in peptides
due to the hydrophobicity of the matrix [88]. This would disrupt the secondary structure of
the peptides and allow for fragmentation near aromatic/hydrophobic residues. Nonenzymatic peptide bond cleavage specific to aromatic residues has not been thoroughly
investigated. We have been studying other peptide systems, such as insulin B-chains in
Chapter 3, to determine whether the peptide cleavages are primary sequence-mediated or
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conformation-specific. These findings are important for better understanding the
implications of peptide fragmentation in LC and give insight into non-enzymatic peptide
cleavage in-vivo.
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CHAPTER EIGHT
CONCLUSIONS AND FUTURE DIRECTIONS
8.1 Conclusions
This work extensively displays how our established LC-IMS-MS workflow can be
applied for the analysis of pancreatic islets at the single-islet and sub-single-islet levels.
Our method can reliably detect pancreatic peptide hormones to elucidate their behaviors
under various conditions, such as corticosterone treatment and under the effects of the
chronic migraine-associated neuropeptides—CGRP and PACAP. We prove that LC-IMSMS possesses the ability to distinguish between mouse Ins1 and Ins2, unlike traditional
methods that fail to separate them. Our studies further reveal the need to distinguish these
insulins, as they display diverged functions and differing behaviors under different
conditions. For instance, corticosterone treatment only significantly affects Ins2 levels,
CGRP exhibits a dual effect on Ins1 depending on oligomeric content, compared to an
inhibitory effect on Ins2, and PACAP only impacts Ins1 levels under glucose stimulation
in-vitro. Additionally, we characterized Ins1 and Ins2, and show they exist in differing
secondary structures and exhibit different aggregation rates due to sequence differences in
the B-chain.
In our work with corticosterone, we showed that Ins2 is better at preserving a folded
conformation that is not found in Ins1. The structural differences between the two isoforms
are likely responsible for their rates of enzymatic degradation in which Ins2 may be a better
substrate for IDE. With our LC-IMS-MS procedure, we reveal new insights into the acute
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corticosterone actions on mouse islets. We show that Ins2, the orthologue of human insulin,
levels decrease significantly with acute corticosterone treatment. Corticosterone actions
also increase the enzymatic activity of endopeptidases within mouse islets, with Ins2 being
hydrolyzed more readily than Ins1. To our knowledge, this is the first study that reports the
differential enzymatic patterns of mouse Ins1 and Ins2 in vivo. Lastly, we show that amylin
levels are increased under corticosterone conditions, implicating the role of corticosterone
in promoting β-cell dysfunction and the development of new-onset hyperglycemia. These
findings provide a molecular basis for the different levels of diabetes risk associated with
the two insulin isoforms. In addition, we showed that short-term exposure to corticosterone
further impairs the level of intact functional insulin. Finally, insulin resistance and
subsequent diabetes development induced by chronic GCs regimens may be due to
fragmentation of insulin, resulting in reduced efficacy of the hormone and/or the
overproduction of amylin, which in humans can aggregate and become toxic to the β-cells.
Investigations into the lessened risk of T2D development in patients with chronic
migraine led to the conclusion that the neuropeptide CGRP is a prime peptide in the
molecular connection between the two diseases. We show that CGRP does not readily
aggregate, and its aggregation is not significantly provoked by Zn2+ complexation.
Moreover, we demonstrate that CGRP can interfere with amylin fibrillization. We show
that neither amylin nor a amylin:CGRP mixture causes direct toxicity to β-cells, but most
likely recruits islet resident macrophages which induce toxicity via inflammation. We
suggest that lowering insulin, and therefore amylin, secretion could lower amylin
accumulation and aggregation thereby preventing cytotoxicity and T2D progression. We
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find that CGRP can independently reduce the secretion of Ins2 but is less effective against
Ins1 to which it can stimulate secretion, a process linked to early diabetic development.
Here, we characterize PACAP for the first time with IMS-MS. Preliminary studies
with PACAP demonstrate that the peptide exists in two main conformers at physiological
pH and readily complexes with amylin and, to a lesser extent, CGRP. Studies of the effects
of PACAP on islet chemistry show that PACAP significantly increases Ins1 secretion
under the stimulation of glucose while having no significant effect on Ins2. In-vivo studies
are proposed to obtain a clearer view of the effects of PACAP on pancreatic peptide
hormones and islet morphology, which will lead to a better understanding of PACAP’s role
in protecting against T2D.
Finally, we show the power of LC-IMS-MS in the detection and characterization
of important posttranslational modifications. Our DTIMS workflow was utilized to
determine whether proline cis/trans isomerization was occurring biologically or due to
TIMS instrumental parameters. Furthermore, we demonstrate the ability of DTIMS to
identify Asn deamidation to Asp and its subsequent isomerization into IsoAsp. Using
MS/MS, we probe the exact Asn (one of two in the peptide studied) that was deamidated
and isomerized. This study demonstrates the capabilities of DTIMS in the study of
posttranslational modifications.

8.2 Future Directions
The work accumulated here serves as a foundation for numerous follow-up studies.
Moving forward, we plan to obtain further structural information and aggregation
propensities on Ins1 and Ins2 and their B-chains through X-ray crystallography, 2D96

infrared spectroscopy (2D-IR), atomic force microscopy (AFM), thioflavin T (ThT)
fluorescence assays, and computer simulations. We also plan to pursue subsequent studies
on the effects of PACAP using transgenic mice overexpression PACAP. MicroMS cell
profiling will also be applied to determine the effects of PACAP on islet morphology.
Finally, we aim to establish an MS-based method to accelerate the discovery of drug
molecules for pancreatic diseases starting with T2D. Our measurements will be performed
at single-islet or sub-single-islet levels where structurally and functionally diverged mouse
Ins1 and Ins2 can be readily distinguished and complemented by high-throughput singlecell profiling and subcellular imaging. Starting with migraine-associated neuropeptides
with activities in pancreatic islets, we will identify peptide analogs that regulate insulin
secretion and remodel human amylin aggregation.
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